Details of the Drug Reposition

General Information of This Drug (ID: DMOIHWI)

• Drug Name: AZD7789 (DMOIHWI)
• Drug Type: Antibody

Information on Drug Reposition of This Drug

2 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Hodgkin lymphoma	DISX2OUL	2B30	Phase 2	[1]
Non-small-cell lung cancer	DISI0V1B	2C25	Phase 2	[2]

References

• [1] ClinicalTrials.gov (NCT05216835) A Phase I/II Open-label, Multi-center Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD7789, an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma. U.S.National Institutes of Health.
• [2] ClinicalTrials.gov (NCT04931654) A Phase I/IIa Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD7789, an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Participants With Advanced or Metastatic Solid Tumors. U.S.National Institutes of Health.